Clinical research is complex.
Sponsors cannot control every variable in a clinical trial.
Recruitment challenges.
Patient adherence.
Biologic variability.
Unexpected safety signals.
These are inherent realities of drug development.
But there is one risk that can be controlled:
Duplicate research subjects entering clinical trials.
And yet, across the industry, this issue continues to compromise patient safety, study integrity, and data reliability.
The Problem Is Larger Than Many Realize
Duplicate participation and professional research subjects are not rare events.
Participants may enroll in multiple studies:
- At different sites
- Within the same study
- Across competing trials
- Across different sponsors
In highly competitive therapeutic areas — such as pain, CNS, vaccines, and metabolic disease — participants often move rapidly between studies seeking compensation.
When this happens, several problems emerge:
- Washout violations
- Prior investigational product exposure
- Altered pharmacologic responses
- Distorted efficacy signals
- Increased safety risk
These issues can compromise both patient safety and study validity.
What You Can Control — 100% of the Time
While many aspects of clinical research involve uncertainty, preventing duplicate enrollment within your own trial is something that can be controlled.
Verified Clinical Trials (VCT) can 100% of the time detect and prevent duplicate subjects within your clinical study.
At the moment of screening, VCT verifies each participant against its research subject database, ensuring that the same individual cannot enroll multiple times within the same trial.
This protection occurs before enrollment, preventing problems rather than discovering them later.
In other words:
Sponsors can ensure that each participant in their study is truly unique.
Portfolio-Level Protection
The same protection can extend beyond a single study.
Sponsors running multiple trials within a development program often face another challenge:
Participants attempting to enroll in multiple studies within the same sponsor portfolio.
For example, a participant may:
- Screen for multiple studies within the same therapeutic area
- Move between Phase II and Phase III programs
- Attempt to re-enroll after prior participation
With VCT implemented across a sponsor’s development program, duplicate participation can be detected and prevented across the entire portfolio.
This ensures that participants do not move between studies within the same organization.
Again, this is something sponsors can fully control.
The Power of the Network
Beyond sponsor-level protection, VCT offers something even more powerful.
Because Verified Clinical Trials operates as a global network, the system can detect and prevent duplicate participation across sponsors and across therapeutic areas.
Participants attempting to move between:
- Different sponsors
- Different CROs
- Different therapeutic areas
- Different geographic regions
can often be identified and prevented.
As more sponsors, CROs, and research sites participate, the network continues to grow stronger.
This expanding ecosystem creates increasing visibility into patterns of professional research subject activity across the clinical research landscape.
Control What You Can Control
Clinical trials will always involve uncertainty.
But duplicate participation does not have to be one of them.
Sponsors cannot control every variable in drug development.
But they can control who enters their trials.
With Verified Clinical Trials, sponsors can ensure:
- 100% prevention of duplicate subjects within their own studies
- 100% protection across their clinical development portfolio
- Increasing protection across sponsors and therapeutic areas through a growing global network
Because when it comes to protecting clinical trials, the most powerful strategy is simple:
Control what you can control.